Metoclopramide

DRUG INFORMATION

  ADULT
    - Symptomatic, Documented Gastroesophageal Reflux in Adults Who Fail Conventional
      Therapy ( 2.1 ) Administer metoclopramide continuously or intermittently:
      Continuous: The recommended dosage is 10 to 15 mg orally, 30 minutes before each
      meal and at bedtime (maximum of 60 mg per day) for 4 to 12 weeks, as determined by
      endoscopic response.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'dosage and
      administration', retrieved 2026-08-29
    - Intermittent: Single doses up to 20 mg prior to provoking situation.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'dosage and
      administration', retrieved 2026-08-29
    - Acute and Recurrent Diabetic Gastroparesis in Adults ( 2.2 ) The recommended
      dosage is 10 mg orally, 30 minutes before each meal and at bedtime (maximum of 40
      mg per day).
      Source: US FDA label for metoclopramide (Metoclopramide), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Metoclopramide is not recommended for use in pediatric patients due to the risk of
      tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of
      methemoglobinemia in neonates. The safety and effectiveness of metoclopramide
      tablets in pediatric patients have not been established.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'pediatric use',
      retrieved 2026-08-29
    - Symptomatic, Documented Gastroesophageal Reflux in Adults Who Fail Conventional
      Therapy ( 2.1 ) Administer metoclopramide continuously or intermittently:
      Continuous: The recommended dosage is 10 to 15 mg orally, 30 minutes before each
      meal and at bedtime (maximum of 60 mg per day) for 4 to 12 weeks, as determined by
      endoscopic response. Intermittent: Single doses up to 20 mg prior to provoking
      situation.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'dosage and
      administration', retrieved 2026-08-29
    - Table 1 displays the recommended daily dosage and maximum daily dosage for adults
      and dosage adjustments for patients with moderate or severe hepatic impairment
      (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute,
      in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with
      strong CYP2D6 inhibitors.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for metoclopramide
      (Metoclopramide), section 'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Dosage Adjustment in Specific Populations ( 2.1 , 2.2 ) For symptomatic,
      documented gastroesophageal reflux and acute and recurrent diabetic gastroparesis,
      see Full Prescribing Information for recommended dosage reductions for elderly
      patients, in patients with moderate or severe hepatic or renal impairment, and
      cytochrome P450 2D6 (CYP2D6) poor metabolizers.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'dosage and
      administration', retrieved 2026-08-29
    - Table 1 displays the recommended daily dosage and maximum daily dosage for adults
      and dosage adjustments for patients with moderate or severe hepatic impairment
      (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute,
      in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with
      strong CYP2D6 inhibitors.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for metoclopramide
      (Metoclopramide), section 'dosage and administration', retrieved 2026-08-29
    - Table 2 displays the recommended daily dosage and maximum daily dosage for adults
      and dosage adjustments for patients with moderate or severe hepatic impairment
      (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute,
      in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with
      strong CYP2D6 inhibitors.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for metoclopramide
      (Metoclopramide), section 'dosage and administration', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Table 1 displays the recommended daily dosage and maximum daily dosage for adults
      and dosage adjustments for patients with moderate or severe hepatic impairment
      (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute,
      in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with
      strong CYP2D6 inhibitors.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for metoclopramide
      (Metoclopramide), section 'dosage and administration', retrieved 2026-08-29
    - Table 2 displays the recommended daily dosage and maximum daily dosage for adults
      and dosage adjustments for patients with moderate or severe hepatic impairment
      (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute,
      in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with
      strong CYP2D6 inhibitors.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for metoclopramide
      (Metoclopramide), section 'dosage and administration', retrieved 2026-08-29
    - Reduce the metoclopramide dosage in patients with moderate and severe renal
      impairment (creatinine clearance less than or equal to 60 mL/minute), including
      those receiving hemodialysis and continuous ambulatory peritoneal dialysis [see
      Dosage and Administration ( 2.1 , 2.2 ), Clinical Pharmacology ( 12.3 )] .
      Source: US FDA label for metoclopramide (Metoclopramide), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Published studies, including retrospective cohort studies, national
      registry studies, and meta-analyses, do not report an increased risk of adverse
      pregnancy-related outcomes with use of metoclopramide during pregnancy.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'pregnancy',
      retrieved 2026-08-29
    - There are potential risks to the neonate following exposure in utero to
      metoclopramide during delivery ( see Clinical Considerations) .
      Source: US FDA label for metoclopramide (Metoclopramide), section 'pregnancy',
      retrieved 2026-08-29
    - In animal reproduction studies, no adverse developmental effects were observed
      with oral administration of metoclopramide to pregnant rats and rabbits at
      exposures about 6 and 12 times the maximum recommended human dose (MRHD) ( see
      Data) .
      Source: US FDA label for metoclopramide (Metoclopramide), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - No evidence of adverse developmental effects due to metoclopramide were observed.
      8.2 Lactation Risk Summary Limited published data report the presence of
      metoclopramide in human milk in variable amounts ( see Data) .
      Source: US FDA label for metoclopramide (Metoclopramide), section 'use in specific
      populations', retrieved 2026-08-29
    - Breastfed infants exposed to metoclopramide have experienced gastrointestinal
      adverse reactions, including intestinal discomfort and increased intestinal gas
      formation ( see Clinical Considerations) .
      Source: US FDA label for metoclopramide (Metoclopramide), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for metoclopramide and any potential adverse
      effects on the breastfed child from metoclopramide or from the underlying maternal
      condition.
      Source: US FDA label for metoclopramide (Metoclopramide), section 'use in specific
      populations', retrieved 2026-08-29